Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
| Autor: | Zhefeng Liu, Shixue Chen, Jinliang Wang, Sujie Zhang, Junxun Ma, Zhaozhen Wu, Huang Di, Haitao Tao, Xuan Zheng, Yi Hu, Pengfei Cui, Xiao Wang, Ruixin Li, Ziwei Huang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Efficacy Poly ADP ribose polymerase Lymphocyte Immunology Poly(ADP-ribose) Polymerase Inhibitors 03 medical and health sciences T790M 0302 clinical medicine Internal medicine Neoplasms medicine Immunology and Allergy Humans Adverse effect PARP inhibitors Immune Checkpoint Inhibitors PI3K/AKT/mTOR pathway 030304 developmental biology Tumors Aged Retrospective Studies Aged 80 and over 0303 health sciences business.industry Retrospective cohort study Middle Aged medicine.disease Survival Analysis Anti-PD-1 Clinical trial medicine.anatomical_structure 030220 oncology & carcinogenesis Original Article Safety business Ovarian cancer |
| Zdroj: | Cancer Immunology, Immunotherapy |
| ISSN: | 1432-0851 0340-7004 |
| Popis: | Background Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. Method Efficacy and safety of PARPi/anti-PD-1 in advanced solid tumors were retrospectively analyzed. The efficacy measures included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). Results This retrospective study included data from 40 patients. The ORR was 27.5% (95% CI, 13.0–42.0%), with a DCR of 85.0% (95% CI, 73.4–96.6%). Except four patients in first-line treatment (three with PR and one with SD), the ORR of ≥second-line treatment, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) was 22.2%, 23.1% and 28.6%, and the DCR was 83.3%, 84.6% and 71.4%, separately. The median PFS of all patients, ≥second-line treatment, NSCLC and SCLC was 4.6 m, 4.2 m, 4.5 m and 3.7 m. The median OS was 9.4 m, 11.4 m, 12.7 m and 5.4 m, respectively. Multivariable analysis revealed that BRCA1/2 mutation was positively correlated with ORR (P = 0.008), and LDH≥250U/L was negatively correlated with lowered DCR (P = 0.018), while lymphocyte number, ECOG and LDH significantly influenced both PFS and OS. We found that the possible resistant mechanisms were sarcomatous degeneration and secondary mutation, including BRCA2 truncation mutation, A2M, JAK1,T790M, KEAP1 and mTOR mutation. 37.5% patients had ≥grade 3 adverse events. Conclusion PARPi/anti-PD-1 is an effective and tolerable method for patients with advanced solid tumors, and BRCA1/2 is a potential biomarker. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink